A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Stopped early · Phase 1

Conditions studied: Acute Myeloid Leukemia

In brief

The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.

Key facts

Study ID

NCT02848248

Run by

Seagen Inc.

People needed

17

Starts

2016-08-01

Expected to finish

2018-04-06

Last updated by the study team

2018-05-14

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed/refractory acute myeloid leukemia following at least 2 but no more than 3 prior regimens
• Patients may be eligible after only 1 previous regimen if in a high risk category
• Adequate baseline renal and hepatic function
• Eastern Cooperative Oncology Group Status of 0 or 1
• CD123-detectable leukemia

You may not qualify if…

• Cerebral/meningeal disease related to underlying malignancy
• Promyelocytic leukemia
• History of clinically significant pulmonary fibrosis or documented diffusing capacity of the lung for carbon monoxide <50% predicted
• Prior hematopoietic stem cell transplant
• Antileukemia or experimental treatment within 4 weeks of study drug (other than hydroxyurea or 6-mercaptopurine)
• Cardio or cerebral vascular event within 6 months

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• City of Hope National Medical Center — Duarte, California, United States
• University of Colorado Hospital / University of Colorado — Aurora, Colorado, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Hudson Valley Hematology and Oncology Associates/New York Medical College — Hawthorne, New York, United States
• MD Anderson Cancer Center / University of Texas — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.